No headlines found.
XOMA Declares Quarterly Preferred Stock Dividends
Globe Newswire (Thu, 21-Mar 7:30 AM ET)
Globe Newswire (Tue, 19-Mar 4:05 PM ET)
Business Wire (Wed, 13-Mar 11:49 AM ET)
Globe Newswire (Fri, 8-Mar 7:30 AM ET)
XOMA to Present at Upcoming Investor Conferences in March
Globe Newswire (Wed, 28-Feb 7:30 AM ET)
Business Wire (Mon, 19-Feb 11:03 AM ET)
PRNewswire (Fri, 16-Feb 2:25 PM ET)
Globe Newswire (Fri, 16-Feb 8:00 AM ET)
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition
Globe Newswire (Thu, 18-Jan 8:30 AM ET)
Globe Newswire (Thu, 11-Jan 4:05 PM ET)
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Xoma trades on the NASDAQ stock market under the symbol XOMA.
As of March 28, 2024, XOMA stock price climbed to $23.90 with 8,470 million shares trading.
XOMA has a beta of -0.08, meaning it tends to be less sensitive to market movements. XOMA has a correlation of 0.00 to the broad based SPY ETF.
XOMA has a market cap of $277.86 million. This is considered a Small Cap stock.
Last quarter Xoma reported $2 million in Revenue and -$1.87 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$1.51.
In the last 3 years, XOMA stock traded as high as $41.99 and as low as $13.48.
The top ETF exchange traded funds that XOMA belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
XOMA has underperformed the market in the last year with a price return of +13.6% while the SPY ETF gained +33.6%. However, in the short term, XOMA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +27.7% vs +10.1% return in SPY. But in the last 2 weeks, XOMA shares have been beat by the market, returning -6.7% compared to an SPY return of +1.7%.
XOMA support price is $22.49 and resistance is $24.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XOMA stock will trade within this expected range on the day.